Qual é o preço para Mega Genomics Limited (6667)

O preço para Mega Genomics Limited (6667) é $0.90379882

Qual é a capitalização de mercado para Mega Genomics Limited (6667)

A capitalização de mercado para Mega Genomics Limited (6667) é $202.72M

Mega Genomics Limited (6667) Margem Operacional

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service that assesses the genetic risk of developing myocardial infarction and heart failure; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing that assesses the cell age and aging rate of a person; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer’s disease; BRCA1/2 gene mutation testing kits; Alzheimer’s disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.

Ano	Margem Operacional	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Margem Operacional

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Margem Operacional	Diferença na Margem Operacional	País
HCA Healthcare, Inc. HCA.US	15.48%	-	US
Fresenius SE & Co. KGaA FRE.DE	0.00%	-	DE
Dr. Sulaiman Al Habib Medical Services Group Company 4013.SR	18.67%	-	SA
Tenet Healthcare Corporation THC.US	16.80%	-	US
IHH Healthcare Berhad 5225.KL	0.00%	-	MY

Empresa

Margem Operacional

Diferença na Margem Operacional

País